Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K, Horinouchi H, Tanaka M, Higashiyama R, Shinno Y, Sato J, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Ohe Y.
Masuda K, et al. Among authors: yoshida t.
J Cancer Res Clin Oncol. 2021 Jan;147(1):245-251. doi: 10.1007/s00432-020-03329-0. Epub 2020 Jul 23.
J Cancer Res Clin Oncol. 2021.
PMID: 32705363
Free PMC article.
Clinical Trial.